Transcatheter arterial chemoembolization combined with percutaneous ethanol injection in the treatment of primary hepatocellular carcinoma-a Meta-analysis
Su Fei,Wang Xin,Chen Shuangqian,Wang Guozhou,Yang Shuailong,Jin Erliang,Li Jiqiang,Xie Wei,Feng Maohui
DOI: https://doi.org/10.3760/cma.j.issn.1001-9030.2014.07.056
2014-01-01
Abstract:Objective To assess the efficacy and adverse events of transcatheter arterial chemoembohzation combined with percutaneous ethanol injection (TACE-PEI) in the treatment of primary hepatocellular carcinoma.Methods Databases such as Pubmed,Cochrane Central,Embase,CNKI,CBMdisc,VIP and WanFang were searched till October 2010,and randomized controlled trims of TACE-PEI in the treatment of primary hepatocellular carcinoma were collected.For all the included studies,we performed Meta-analysis using RevMan 5.1.Results Twenty-one literatures were reviewed,including 774 cases receiving TACE-PEI and 740 cases receiving TACE.Meta-analysis revealed the 1-year survival rate [OR =3.44,95％ confidence interval (CI) (2.60-4.55),P ＜ 0.01],2-year survival rate [OR =2.96,95％ CI (2.29-3.83),P ＜0.01],3-year survival rate [OR=3.54,95％CI (2.53-4.97),P＜0.01],the decrease of AFP [OR =3.14,95％ CI(2.30-4.28),P ＜ 0.01],and shrinkage of tumor mass [OR =3.05,95％ CI(2.30-4.03),P ＜0.01] in TACE-PEI group were significantly higher than in TACE group.The adverse events [OR =1.94,95％ CI (1.17-3.21),P ＜ 0.05] were also more frequently seen in TACEPEI group than in TACE group.Conclusion The efficacy of TACE-PEI in the treatment of primary hepatocellular carcinoma was superior to that of TACE alone.However,the combination of TACE-PEI increased the adverse events.